Von Willebrand disease (VWD) is treated with a combination of medications that either boost your body’s own clotting protein or replace it directly. The right approach depends on which type you have (1, 2, or 3) and the severity of your bleeding. Most people with VWD can manage their condition effectively and live without major restrictions, but treatment needs to be tailored carefully because what works for one type can actually be harmful in another.
Desmopressin: The First Option for Milder Types
For most people with Type 1 VWD, the first treatment tried is a synthetic hormone called desmopressin (often referred to by its brand name, DDAVP). It works by signaling your body to release stored von Willebrand factor (VWF) from the lining of your blood vessels, temporarily raising your levels enough to control or prevent bleeding. It can be given through an IV, injected under the skin, or sprayed into the nose.
Desmopressin works well for a large share of Type 1 patients. In one single-center review published in Haemophilia, about 89% of patients met the threshold for a good response, though the success rate ranged from roughly 53% to 92% depending on how “response” was defined. Because of this variability, most treatment centers will do a trial dose before you actually need it, so your care team knows in advance whether desmopressin is a reliable option for you.
The main safety concern with desmopressin is that it causes your body to retain water, which can dilute sodium levels in your blood. This is especially important in children and anyone receiving multiple doses. The standard precaution is to limit fluid intake to about two-thirds of normal for 24 hours after each dose. One pediatric study found that when families followed this protocol, no children developed dangerous sodium drops, though mild, symptom-free dips occurred in a few cases where fluid restriction wasn’t closely followed.
When Desmopressin Won’t Work
Desmopressin is not appropriate for every type of VWD. In Type 2B, the von Willebrand factor itself is abnormal: it binds too aggressively to platelets. Releasing more of it with desmopressin can actually pull platelets out of circulation, worsening a low platelet count and making bleeding harder to control. For this reason, desmopressin is generally considered contraindicated in Type 2B, although some specialists have used it cautiously in patients whose platelet counts are normal at baseline.
People with Type 3 VWD produce little to no von Willebrand factor at all, so there’s nothing stored in the blood vessels for desmopressin to release. These patients, along with many with Type 2 subtypes, need direct replacement therapy instead.
Factor Replacement Therapy
When your body can’t produce enough functional VWF on its own, the protein can be replaced through an infusion. There are currently four VWF concentrate products available in the United States, and they are not interchangeable. Three are derived from donated human plasma (Alphanate, Humate-P, and Wilate), and one, Vonvendi, is a recombinant product made without human blood.
The key difference between these products is what they contain. Most plasma-derived concentrates include both VWF and clotting factor VIII bundled together, in varying ratios. Vonvendi contains only VWF, so factor VIII must be given separately if needed. Your hematologist chooses between them based on the specific ratio of proteins your situation requires and how your body responds.
Factor replacement is used in two main ways. It can be given on demand, meaning you receive an infusion when bleeding starts or just before a procedure. For people with severe VWD who bleed frequently, the 2021 guidelines from the American Society of Hematology and partner organizations recommend long-term prophylaxis: regular infusions on a set schedule to prevent bleeds before they happen. How often and how long you need prophylaxis is reassessed periodically based on your bleeding pattern.
Antifibrinolytic Medications
Antifibrinolytics are medications that help stabilize blood clots once they’ve formed. They don’t raise your VWF levels, but they prevent your body from breaking down clots too quickly. The two most common are tranexamic acid and aminocaproic acid, both taken by mouth.
These drugs are especially useful for bleeding in the mouth, nose, or during heavy periods, where the body’s natural clot-dissolving enzymes are particularly active. They’re often used alongside desmopressin or factor replacement rather than on their own. Tranexamic acid is typically dosed based on body weight every 8 to 12 hours, while aminocaproic acid is given more frequently, every 4 to 6 hours. Your care team will set the exact schedule based on the situation.
Managing Heavy Periods
Heavy menstrual bleeding is one of the most common symptoms of VWD in women, and it’s often the reason VWD gets diagnosed in the first place. Current guidelines recommend hormonal therapy as a first-line treatment for this specific problem. Options include combination birth control pills, progestin-only injections, hormonal IUDs, implants, and vaginal rings.
In a study of 269 women with Type 1 VWD enrolled in the Zimmerman Program, 103 were using some form of hormonal therapy. Oral contraceptives were the most common choice by far, used by 71 of those women. Research has shown that hormonal contraceptives can reduce menstrual blood loss by 35% to 69%, though the benefit varies widely from person to person. Women using hormonal therapy in the Zimmerman study did trend toward lower bleeding scores compared to non-users (6.8 vs. 7.4 on a standardized scale), though the difference wasn’t statistically significant. Hormonal therapy doesn’t change your underlying VWF levels. It works by thinning the uterine lining, so there’s simply less tissue to shed each month.
For women who don’t respond well enough to hormonal therapy alone, tranexamic acid during periods or desmopressin can be added. Some women use a combination of all three approaches.
Preparing for Surgery or Dental Work
Any planned procedure, from a tooth extraction to a major surgery, requires advance coordination with your hematologist. The goal is to raise your VWF and factor VIII levels to a safe range before the first incision and keep them there throughout healing. For minor procedures, this might mean a single dose of desmopressin or a short course of tranexamic acid. For major surgery, it typically involves factor concentrate infusions that continue for several days afterward.
For dental procedures specifically, local measures add another layer of protection. Fibrin sealants (a type of biological glue made from clotting proteins) can be applied directly to the surgical site. Thrombin-soaked gauze, held against the wound for 5 to 10 minutes, is another option that promotes clot formation right where it’s needed. These topical tools work best when paired with systemic treatment rather than used alone.
Long-Term Prophylaxis for Severe Cases
Most people with Type 1 VWD only need treatment around bleeding episodes or procedures. But for those with Type 3 or severe Type 2 who experience frequent spontaneous bleeds, particularly into joints or the digestive tract, regular preventive infusions of VWF concentrate can significantly reduce bleeding episodes. This is similar to the prophylaxis approach used in hemophilia.
Prophylaxis schedules are individualized. Some people infuse two to three times per week, while others may need it less often. The 2021 ASH guidelines note that the evidence base for prophylaxis in VWD is still limited, so the decision is typically made based on your personal bleeding history rather than a one-size-fits-all protocol. Your need for prophylaxis should be reassessed over time, since bleeding patterns can shift with age, activity level, and life changes like pregnancy or menopause.
Matching Treatment to Your Type
The single most important factor in VWD treatment is knowing your exact subtype. Here’s a simplified breakdown:
- Type 1 (most common, about 70-80% of cases): VWF levels are low but the protein works normally. Desmopressin is usually effective. Antifibrinolytics and hormonal therapy for periods round out the approach.
- Type 2A, 2M, 2N: The VWF is present but doesn’t function correctly. Desmopressin may help some patients, but many need factor replacement. A trial dose determines which route works.
- Type 2B: Desmopressin is generally avoided due to the risk of dropping platelet counts. Factor replacement is the standard approach.
- Type 3 (rarest and most severe): No VWF is produced. Factor replacement is required for all significant bleeding, and long-term prophylaxis is often recommended.
Getting a desmopressin trial early, before you need emergency treatment, lets your care team build a clear plan so you’re never guessing in a crisis. Carrying medical identification that lists your VWD type and your known treatment response is a practical step that can make a real difference if you’re ever treated by providers who don’t know your history.